BIOMAT Database Logo BIOMAT Database Logo

Convalescent Plasma Versus Hyperimmune Immunoglobulins. 2023

Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

UI MeSH Term Description Entries
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19

Related Publications

Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
[Immunoglobulins (hyperimmune plasma) of specific activity].
July 1977, Sovetskaia meditsina,
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
[Hyperimmune immunoglobulins].
November 1983, Presse medicale (Paris, France : 1983),
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Convalescent plasma and hyperimmune globulin therapy in COVID-19.
April 2021, Expert review of clinical immunology,
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study.
April 2024, Clinical pharmacokinetics,
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19.
July 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
April 2023, Process biochemistry (Barking, London, England),
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
June 2021, Transfusion,
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma.
February 2022, The Journal of infectious diseases,
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19.
January 2020, The Pan African medical journal,
Daniele Focosi, and Massimo Franchini, and Emanuele Nicastri, and David J Sullivan, and Arturo Casadevall
Immunoglobulins in hyperimmune horse serum.
June 1968, Indian journal of biochemistry,
Copied contents to your clipboard!